Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03645486
NA

Lentiviral Gene Therapy for CGD

Sponsor: Shenzhen Geno-Immune Medical Institute

View on ClinicalTrials.gov

Summary

This is a Phase I/II clinical trial of gene therapy for treating Chronic Granulomatous Disease using a high-safety, high-efficiency, self-inactivating lentiviral vector TYF to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the TYF-CGD gene transfer clinical protocol.

Official title: Lentiviral Gene Therapy for Chronic Granulomatous Disease (CGD)

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2025-07-01

Completion Date

2029-12-31

Last Updated

2026-04-24

Healthy Volunteers

No

Interventions

GENETIC

Infusion of lentiviral TYF-CGD-modified autologous stem cells

Infusion of lentiviral TYF-modified autologous stem cells at 1\~10x10\^6 gene-modified cells per kg body weight

Locations (1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China